Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284443 | 0.83 | BCHE (0.40) | EGFRCXCR4APPBCHEACHE | |
| SCHEMBL8285518 | 0.81 | HRH3 (0.39) | EGFRCXCR4APPBCHEACHE | |
| SCHEMBL8284411 | 0.79 | NME2 (0.40) | CXCR4APPBCHEACHELMNA | |
| SCHEMBL4860786 | 0.79 | TRPC5 (0.39) | EGFRALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4864386 | 0.78 | TRPC5 (0.38) | ALDH1A1MEN1KMT2AHSD17B10CASP1 | |
| SCHEMBL8284441 | 0.77 | TRPC5 (0.42) | EGFRCXCR4APPBCHEACHE | |
| SCHEMBL8285134 | 0.77 | ALDH1A1 (0.38) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4863925 | 0.77 | BCHE (0.37) | EGFRCXCR4APPBCHEACHE | |
| SCHEMBL4862701 | 0.76 | TRPC5 (0.38) | EGFRALDH1A1TP53MEN1KMT2A | |
| SCHEMBL4856032 | 0.75 | PIK3C2B (0.39) | ALDH1A1MEN1KMT2AKDM4ECASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883837-B2 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-11 | — | — | US | disclosed |
| US-8883837-B2 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-11 | — | — | US | disclosed |
| US-8883837-B2 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-11 | — | — | US | disclosed |
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2008-11-13 | — | — | US | disclosed |
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2008-11-13 | — | — | US | disclosed |
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2008-11-13 | — | — | US | disclosed |
| US-7449463-B2 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-11-11 | — | — | US | disclosed |
| US-7449463-B2 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-11-11 | — | — | US | disclosed |
| US-7449463-B2 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-11-11 | — | — | US | disclosed |
| EP-1697345-B1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | disclosed |
| WO-2005058871-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | RIN1, ZC3HAV1L, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 3786/4885CXCR4 1047/4885APP 4814/4885 |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3 | EGFR 3364/4885CXCR4 1313/4885APP 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.